Bioresorbable Drug-Eluting Magnesium-Alloy Scaffold for Treatment of Coronary Artery Disease

Carlos M. Campos,Takashi Muramatsu,Javaid Iqbal,Ya-Jun Zhang,Yoshinobu Onuma,Hector M. Garcia-Garcia,Michael Haude,Pedro A. Lemos,Boris Warnack,Patrick W. Serruys,Carlos Campos,Yao-Jun Zhang,Hector Garcia-Garcia,Pedro Lemos,Patrick Serruys
DOI: https://doi.org/10.3390/ijms141224492
IF: 5.6
2013-12-16
International Journal of Molecular Sciences
Abstract:The introduction of metallic drug-eluting stents has reduced the risk of restenosis and widened the indications of percutaneous coronary intervention in treatment of coronary artery disease. However, this medical device can induce hypersensitive reaction that interferes with the endothelialization and healing process resulting in late persistent or acquired malapposition of the permanent metallic implant. Delayed endotheliaization and malapposition may lead to late and very late stent thrombosis. Bioresorbable scaffolds (BRS) have been introduced to potentially overcome these limitations, as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage. Magnesium is an essential mineral needed for a variety of physiological functions in the human body and its bioresorbable alloy has the strength-to-weight ratio comparable with that of strong aluminum alloys and alloy steels. The aim of this review is to present the new developments in Magnesium BRS technology, to describe its clinical application and to discuss the future prospects of this innovative therapy.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?